Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Delcath cancer news

Delcath said it will reduce headcount by 20% and will focus on its clinical development program and European commercialization of its Hepatic

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE